Key US Patents Granted for GPCR-Focused Drug Discovery Platform
MRC Technology (MRCT) is pleased to highlight that Heptares Therapeutics (Heptares) recently announced the grant of multiple key patents in the US relating to its GPCR-focused drug discovery platform. Heptares was formed in 2007 as a spin-out from the Medical Research Council’s (MRC’s) Laboratory of Molecular Biology and National Institute of Medical Research, where the pioneering technology originated.
The patents granted cover Heptares’ technology platform for the creation of thermostabilised GPCRs (or StaR proteins) and their use for drug screening and structure-based drug design. The company focuses on new medicines targeting previously undruggable or challenging GPCRs linked to a wide range of human disease, including Alzheimer’s disease, attention deficit hyperactivity disorder, diabetes, schizophrenia and migraine. GPCRs provide an almost universal mechanism for transmitting signals into and out of cells. There are over 800 GPCRs encoded by the human genome and each one is specific to a particular signal. Approximately 30–40% of all drugs marketed across all conditions act on GPCRs, making them one of the most important drug target families known.
Dave Tapolczay, MRC Technology’s CEO, said: “We are delighted by this news as it is a further example of how MRC Technology can assist in translating pioneering research into commercial and therapeutic reality. The smooth and robust transition of IP from MRC to the new company was of particular importance and seeing Heptares go on to build a strong internally generated global patent estate is testament to the founding work of MRCT’s IP team. We wish Heptares every success in bringing new GPCR-based therapies to patients.”
Malcolm Weir, CEO of Heptares, added: “I joined MRCT in 2006 and, with our CSO Fiona Marshall and colleagues from MRC’s Laboratory of Molecular Biology, formed Heptares the following year. The grant of these US patents is another significant milestone in the company’s development and one it would not have reached without MRC’s original first-class science and the ongoing ‘translational’ support from MRCT.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance